Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Body Weight and Height in Adolescent NHL

Cancer; ePub Feb 22; Leiba M, Leiba A

Publish date:: March 2, 2016

Higher body weight and taller stature during adolescence are associated with an increased risk of non-Hodgkin lymphoma (NHL) and may modestly contribute to its increasing incidence. This according to a study of 2,352,988 Israeli adolescents, aged 16 to 19 years. Researchers found:

• Adolescent overweight and obesity were associated with a hazard ratio (HR) of 1.25 for NHL vs normal weight.

• There was a graded association of height with NHL, with the tallest (≥ 95^th percentile) having an HR of 1.28 vs those in the 25^th to < 50^th percentiles.

• Marginal zone lymphoma, primary cutaneous lymphoma (PCL), and diffuse large B-cell lymphoma (DLBCL) showed the strongest associations for overweight/obesity.

• DLBCL and PCL showed the strongest associations for height.

Citation: Leiba M, Leiba A, Keinan-Boker L, et al. Adolescent weight and height are predictors of specific non-Hodgkin lymphoma subtypes among a cohort of 2,352,988 individuals aged 16 to 19 years. [Published online ahead of print February 22, 2016]. Cancer. doi: 10.1002/cncr.29792.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Aggressive Lymphomas

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL,

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,